Evidence map›Paper›PMID 40293950›Full record

ArticleCancer research communications2025

Inferring Drug-Gene Relationships in Cancer Using Literature-Augmented Large Language Models.

Ying-Ju Lai, Li-Ju Wang, Tyler M Yasaka, Yuna Shin, Michael Ning, Yanhao Tan, Chien-Hung Shih, Yibing Guo, Po-Yuan Chen, Hugh Galloway and 6 more

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ying-Ju Lai *UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-5444-4040
Li-Ju Wang *UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0009-0005-5385-459X
Tyler M YasakaUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-8482-0369
Yuna ShinUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0009-0002-2739-4620
Michael NingUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0009-0004-5353-8610
Yanhao TanUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0003-4296-5241
Chien-Hung ShihUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0009-0006-3633-7838
Yibing GuoUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0001-8098-7682
Po-Yuan ChenUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0003-0936-4102
Hugh GallowayUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0009-0005-6526-8889
Zhentao LiuUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-1061-7042
Arun DasUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0001-7512-0523
George C TsengDepartment of Biostatistics and Health Data Science, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-5447-1014
Satdarshan P MongaUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-8437-3378
Yufei HuangUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0001-6268-5357
Yu-Chiao ChiuUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0003-1647-8634

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shuchang Silvia Liu · 2019 to 2026
$10.9M
Cellular Approaches to Tissue Engineering/RegenerationT32EB001026 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUNCAN, ANDREW W, MONGA, SATDARSHAN SINGH · 2003 to 2024
$5.5M
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCCR01CA251155 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LUJAMBIO, AMAIA, MONGA, SATDARSHAN SINGH · 2020 to 2024
$3.1M
Investigating Multifactorial Beta-catenin Activation in Hepatocellular CancersR01CA250227 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Xin Chen, Satdarshan Singh Monga · 2021 to 2026
$3.0M
m6A-suite: an informatics pipeline and resource for elucidating roles of m6A epitranscriptome in cancerU01CA279618 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HUANG, YUFEI · 2023 to 2025
$1.8M
Disease subtyping guided by clinical phenotype for precision medicineR01LM014142 · NLM · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI George C. Tseng · 2023 to 2026
$1.2M
Single-cell congruence evaluation and selection of cancer models towards precision medicineR01CA285337 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Adrian V Lee, George C. Tseng · 2025 to 2026
$1.2M
Novel computational approaches for pharmacogenomics of complex diseasesR35GM154967 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Yu-Chiao Chiu · 2024 to 2026
$1.2M
Enhancing AI-readiness of multi-omics data for cancer pharmacogenomicsR00CA248944 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHIU, YU-CHIAO · 2022 to 2024
$1.1M
High-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574k
Novel geometric deep learning models for tissue structure-aware spatial expression representations from spatially resolved single-cell transcriptomics dataR21GM155774 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GAO, SHOU-JIANG, HUANG, YUFEI · 2024 to 2025
$433k
NCI NIH HHS P30 CA047904NCI NIH HHS R00 CA248944NCI NIH HHS R01 CA250227NCI NIH HHS R01 CA251155NCI NIH HHS R01 CA285337NCI NIH HHS U01 CA279618NIBIB NIH HHS T32 EB001026NIDDK NIH HHS P30 DK120531NIGMS NIH HHS R21 GM155774NIGMS NIH HHS R35 GM154967NIH HHS R03 OD036494NIH HHS S10 OD028483NLM NIH HHS R01 LM014142
6 · The paper itself

Abstract

abstractUnderstanding drug–gene relationships is essential for advancing targeted cancer therapies and drug repurposing strategies. However, the vast volume of biomedical literature poses significant challenges in efficiently extracting relevant insights. In this study, we developed an automated pipeline that leverages retrieval-augmented large language models (LLM) to infer drug–gene interactions using the most up-to-date biomedical literature. By integrating PubMed and state-of-the-art LLMs, our pipeline generates accurate, evidence-based inferences while addressing the limitations of static LLMs, such as outdated knowledge and the risk of producing misleading results. We systematically validated the pipeline’s performance using curated databases and demonstrated its ability to accurately identify both well-established and emerging drug targets. Using our pipeline, we constructed a pan-cancer drug–gene interaction network among hundreds of FDA-approved drugs and key oncogenes. In a case study on liver cancer, we identified and validated an association between CTNNB1 mutations and enhanced sensitivity to sorafenib, highlighting a potential therapeutic strategy for this challenging mutation. To facilitate broad accessibility, we developed GeneRxGPT, a user-friendly web application that enables cancer researchers to utilize the pipeline without programming expertise or extensive computational resources. It provides intuitive modules for drug–gene inference and network visualization, streamlining the exploration and interpretation of drug–gene relationships. We anticipate that GeneRxGPT will empower researchers to accelerate drug discovery and development, making it a valuable resource for the cancer research community. SIGNIFICANCE: This study presents a novel approach that integrates LLMs with real-time biomedical literature to uncover drug-gene relationships, transforming how cancer researchers identify therapeutic targets, repurpose drugs, and interpret complex molecular interactions. GeneRxGPT, our user-friendly tool, enables researchers to leverage this approach without requiring computational expertise.

Indexed as

Antineoplastic AgentsComputational BiologyNeoplasmsHumansLarge Language ModelsAntineoplastic Agents

Identifiers

PMID40293950
PMCPMC12036822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.